Search Results - "Tannock, I.F"

Molecular screening to select therapy for advanced cancer? by Tannock, I.F., Hickman, J.A.

Get full text

Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop by Vardy, J., Wefel, J. S., Ahles, T., Tannock, I. F., Schagen, S. B.

“…A subset of survivors has cognitive impairment after cancer treatment. This is generally subtle, but may be sustained. In October 2006, the second…”
Get full text

Cognitive function and fatigue after diagnosis of colorectal cancer by Vardy, J., Dhillon, H.M., Pond, G.R., Rourke, S.B., Xu, W., Dodd, A., Renton, C., Park, A., Bekele, T., Ringash, J., Zhang, H., Burkes, R., Clarke, S.J., Tannock, I.F.

“…Cognitive impairment and fatigue have been associated with cancer and its treatment. We present baseline data from a large longitudinal study that evaluates…”
Get full text

9 New developments in the systemic treatment of advanced prostate cancer by Tannock, I.F

Get full text

How valid are claims for synergy in published clinical studies? by Ocana, A., Amir, E., Yeung, C., Seruga, B., Tannock, I.F.

“…Clinical trials evaluating drug combinations are often stimulated by claims of synergistic interactions in preclinical models. Overuse or misuse of the term…”
Get full text

1229 Industry-Sponsored Posters at Major Oncology Conferences: Science or Marketing? by Guerra, R.B, Toloi, D, Tibau, A, Ocana, A, Seruga, B, Vera-Badillo, F, Amir, E, Tannock, I.F, Templeton, A.J

Get full text

Randomized, Double-Blind, Controlled Trial of Mitoxantrone/Prednisone and Clodronate Versus Mitoxantrone/Prednisone and Placebo in Patients With Hormone-Refractory Prostate Cancer and Pain by ERNST, D. S, TANNOCK, I. F, WINQUIST, E. W, VENNER, P. M, REYNO, L, MOORE, M. J, CHI, K, DING, K, ELLIOTT, C, PARULEKAR, W

“…To compare the incidence of palliative response in patients with hormone-resistant prostate cancer (HRPC) treated with mitoxantrone and prednisone (MP) plus…”
Get full text

1973 Epidermal growth factor receptor (EGFR) over-expression and outcomes in early breast cancer: A systematic review and meta-analysis by Vera Badillo, F.E, Gonzalez-Guerrero, J.F, Gonzalez-Conchas, G.A, Rodriguez-Fernandez, I.A, Verdines-Perez, A, Templeton, A, Ocana, A, Seruga, B, Tannock, I.F, Amir, E

Get full text

2589 Adjuvant radiation therapy after radical nephrectomy in patients with localized renal cell carcinoma: a systematic review and meta-analysis by Badillo, F.E. Vera, Gonzalez-Guerrero, J.F, Rodriguez-Fernandez, I.A, Gonzalez-Conchas, I.A, Verdines-Perez, A, Templeton, A.J, Ocana, A, Seruga, B, Tannock, I.F, Amir, E

Get full text

Can we afford the future: effectiveness or cost-effectiveness as the criterion for introducing new therapies for breast cancer? by Tannock, I.F

Get full text

Should Personalised Medicine Be Funded in Countries with Limited Resources? by Tannock, I.F.

Get full text

117INSHOULD PERSONALISED MEDICINE BE FUNDED IN COUNTRIES WITH LIMITED RESOURCES? by Tannock, I.F.

“…Abstract Personalised medicine implies that treatment is based on molecular analysis of an individual tumour specimen. A biomarker may define groups of…”
Get full text

If and When to Start Systemic Therapy As Palliation for People with Advanced Cancer by Tannock, I.F.

Get full text

106INIF AND WHEN TO START SYSTEMIC THERAPY AS PALLIATION FOR PEOPLE WITH ADVANCED CANCER by Tannock, I.F.

“…Abstract To benefit patients, treatment must improve either duration or quality of survival. For patients with minimal symptoms, one should only start…”
Get full text

Have investigators forgotten how to write? by Tannock, I.F.

Get full text

Improving access to immunotherapy in low- and middle-income countries by Patel, A., Goldstein, D.A., Tannock, I.F.

Get full text

How low can you go? PD-L1 expression as a biomarker in trials of cancer immunotherapy by Fundytus, A., Booth, C.M., Tannock, I.F.

Get full text

Rules for the conduct of clinical trials need revision, but ‘good clinical practice’ requires much more by Salawu, A., Tannock, I.F.

Get full text

Disclosure—in the blink of an eye by Tannock, I.F.

Get full text

Flawed trials for cancer by Tannock, I.F., Templeton, A.J.

Get full text